VEGF, LN-R在卵巢癌中的表达及临床意义
摘要
目的探讨血管内皮生长因子(vascular endothelial growth factor,VEGF)和层粘连蛋白受体(lmainin recepetor,LN-R)在卵巢癌发生和发展中的作用和临床意义。
方法用免疫组织化学SP法检测19例正常卵巢组织、23例良性卵巢肿瘤及42例卵巢癌组织中VEGF和LN-R的表达,用卡方检验和Sperman相关分析统计结果,计算出P值。分析其表达与肿瘤病理类型、组织学分级、FIGO临床分期、有无转移的关系。
结果1.VEGF在正常卵巢组织、良性卵巢肿瘤及卵巢癌中的阳性表达分别为10.5%、43.4%及73.8%。良性卵巢肿瘤与正常卵巢组织中VEGF的阳性表达率有显著差异(P<0.05),卵巢癌与良性卵巢肿瘤中VEGF的阳性表达率有显著差异(P<0.05)。
2.VEGF在卵巢浆液性囊腺癌中的阳性表达率为76%,在卵巢非浆液性囊腺癌中阳性表达率为70.6%。两组VEGF阳性表达率无显著性差异(χ2=0.153,P>0.05)；VEGF在低分化组中的阳性表达率为90.9%,明显高于高中分化组的阳性表达率55%(χ2=6.98,P<0.05)；VEGF在Ⅲ期-Ⅳ期中的阳性表达率为86.9%,显著高于Ⅰ期-Ⅱ期VEGF阳性表达率57.8%(χ2=4.54,P<0.05)；VEGF在伴有淋巴结或大网膜转移的卵巢癌组织中阳性表达率86.4%,明显高于不伴有淋巴结或大网膜转移的卵巢癌组织VEGF的阳性表达率55%(χ2=5.05,P<0.05)。
3.LN-R在正常卵巢组织中不表达,在良性卵巢肿瘤中阳性表达率为4.3%,在卵巢癌中的阳性表达率为76.2%。LN-R在卵巢癌与良性卵巢肿瘤中的阳性表达率有显著差异(P<0.05)。
4.LN-R在卵巢浆液性囊腺癌中的阳性表达率为76%,在卵巢非浆液性囊腺癌中阳性表达率为76.5%。两组LN-R的阳性表达率无显著性差异(x2=0.001,P>0.05)；LN-R在低分化组阳性表达率为90.9%,明显高于高中分化组的阳性表达率60%(x2=5.51,P<0.05)；LN-R在Ⅲ期-Ⅳ期中阳性表达率为91.3%,显著高于Ⅰ期-Ⅱ期中的阳性表达率57.8%(x2=6.40,P，0.05)；LN-R在伴有淋巴结或大网膜转移的卵巢癌组织中阳性表达率为81.8%,明显高于不伴有淋巴结或大网膜转移的卵巢癌组织中的阳性表达率50%(x2=4.77,P<0.05)。
5.卵巢癌中VEGF的表达与LN-R的表达有相关性(P<0.05)。
结论
1.VEGF和LN-R在卵巢肿瘤的发生、发展过程中起着一定的作用。
2.两指标与卵巢癌的临床期别、癌细胞分化程度以及有无大网膜、淋巴结转移有关,提示VEGF和LN-R可作为临床上预测卵巢癌预后的指标。
3.在卵巢癌中VEGF和LN-R表现出一定的相关性,在卵巢癌发生和发展中呈协同作用。提示两者在卵巢肿瘤的发生发展中可能有着较为密切的联系。
Objective:
To explore the role and clinical significance of vascular endothelial growth factor(VEGF)) and lmainin recepetor (LN-R) in ovarian cancer.
Methods:
Using method of Immunohistochemical SP, the expression of VEGF and LN-R in 19 cases of normal ovarian tissues,23 cases of benign ovarian tumors and 42 cases of ovarian cancer were detected. Statistical analysis was performed with chi-square test and Sperman correlation.The relationship of their expression and pathological type, histological grade, FIGO stage, whether having metastasis were analysised.
Results:
1. The positive expression of VEGF in normal ovarian tissues and benign ovarian tumors and ovarian cance were 10.5%,43.4% and 73.8%,respectively.The positive expression rate of VEGF was significantly different in normal ovarian tissue and benign ovarian tumor tissue (P<0.05) and also was significantly different in benign ovarian tumor and ovarian cancer.(P<0.05)
2. The positive expression rate of VEGF in ovarian serous adenocarcinoma was 76%,that in other ovarian cancers was 70.6%. The difference of VEGF positive expression rate of the two groups was unsignificant (χ2=0.153, P>0.05); The positive expression rate of VEGF in the poorly differentiated group (90.9%) was significantly higher than that in the high differentiated group (55%) (χ2=6.98, P<0.05);The rate of positive expression of VEGF in StageⅢ-Ⅳ(86.9%) was significantly higher than that in the stageⅠ-Ⅱ(57.8%) (χ2=4.54, P<0.05); In the ovarian cancer tissues with lymph nodes or omentum metastasis,the VEGF positive expression rate was 86.4%, significantly higher than that without metastasis (55%)(χ=5.05, P<0.05)
3. LN-R did not express in normal ovarian tissue,LN-R expressed in benign ovarian tumors with low level (4.3%),with high levels of expression in ovarian cancer (76.2%). The positive expression rate of LN-R was significantly different between benign ovarian tumor and ovarian cancer.(P<0.05)
4. The positive expression rate of LN-R in ovarian serous adenocarcinoma was 76%, that in other ovarican cancer was 76.5%. LN-R positive expression rate of the two groups had no significant difference (χ2=0.001, P>0.05); The positive expression rate of LN-R in the poorly differentiated group (90.9%)was significantly higher than that in the high differentiated group(60%) (χ2=5.51, P<0.05); The positive expression of LN-R in stageⅢ-Ⅳ(91.3%) was significantly higher than that in the stageⅠ-Ⅱ(57.8%) (χ2 =6.40, P<0.05); The positive expression rate of LN-R in ovarian cancer with lymph nodes or omentum metastasis(81.8%) was significantly higher than that without lymph nodes or omentum metastasis (50%)(χ2=4.77, P<0.05)
5.VEGF and LN-R show some positive correlation in the occurrence and development of ovarian cancer. (P<0.05)
Conclusions:
1. VEGF and LN-R play a role in the occurrence and development of ovanan cancer.
2. The positive expression of VEGF and LN-R has relationship with clinical stage and histological grading, lymph nodes or omentum metastasis, and has no relationship with pathological type; which indicated that VEGF and LN-R could predict prognostics of ovarian cancer.
3. VEGF and LN-R show some correlation in the occurrence and development of ovarian cancer, which indicated that they cooperated in the occurrence and development of ovarian cancer.
方法用免疫组织化学SP法检测19例正常卵巢组织、23例良性卵巢肿瘤及42例卵巢癌组织中VEGF和LN-R的表达,用卡方检验和Sperman相关分析统计结果,计算出P值。分析其表达与肿瘤病理类型、组织学分级、FIGO临床分期、有无转移的关系。
结果1.VEGF在正常卵巢组织、良性卵巢肿瘤及卵巢癌中的阳性表达分别为10.5%、43.4%及73.8%。良性卵巢肿瘤与正常卵巢组织中VEGF的阳性表达率有显著差异(P<0.05),卵巢癌与良性卵巢肿瘤中VEGF的阳性表达率有显著差异(P<0.05)。
2.VEGF在卵巢浆液性囊腺癌中的阳性表达率为76%,在卵巢非浆液性囊腺癌中阳性表达率为70.6%。两组VEGF阳性表达率无显著性差异(χ2=0.153,P>0.05)；VEGF在低分化组中的阳性表达率为90.9%,明显高于高中分化组的阳性表达率55%(χ2=6.98,P<0.05)；VEGF在Ⅲ期-Ⅳ期中的阳性表达率为86.9%,显著高于Ⅰ期-Ⅱ期VEGF阳性表达率57.8%(χ2=4.54,P<0.05)；VEGF在伴有淋巴结或大网膜转移的卵巢癌组织中阳性表达率86.4%,明显高于不伴有淋巴结或大网膜转移的卵巢癌组织VEGF的阳性表达率55%(χ2=5.05,P<0.05)。
3.LN-R在正常卵巢组织中不表达,在良性卵巢肿瘤中阳性表达率为4.3%,在卵巢癌中的阳性表达率为76.2%。LN-R在卵巢癌与良性卵巢肿瘤中的阳性表达率有显著差异(P<0.05)。
4.LN-R在卵巢浆液性囊腺癌中的阳性表达率为76%,在卵巢非浆液性囊腺癌中阳性表达率为76.5%。两组LN-R的阳性表达率无显著性差异(x2=0.001,P>0.05)；LN-R在低分化组阳性表达率为90.9%,明显高于高中分化组的阳性表达率60%(x2=5.51,P<0.05)；LN-R在Ⅲ期-Ⅳ期中阳性表达率为91.3%,显著高于Ⅰ期-Ⅱ期中的阳性表达率57.8%(x2=6.40,P，0.05)；LN-R在伴有淋巴结或大网膜转移的卵巢癌组织中阳性表达率为81.8%,明显高于不伴有淋巴结或大网膜转移的卵巢癌组织中的阳性表达率50%(x2=4.77,P<0.05)。
5.卵巢癌中VEGF的表达与LN-R的表达有相关性(P<0.05)。
结论
1.VEGF和LN-R在卵巢肿瘤的发生、发展过程中起着一定的作用。
2.两指标与卵巢癌的临床期别、癌细胞分化程度以及有无大网膜、淋巴结转移有关,提示VEGF和LN-R可作为临床上预测卵巢癌预后的指标。
3.在卵巢癌中VEGF和LN-R表现出一定的相关性,在卵巢癌发生和发展中呈协同作用。提示两者在卵巢肿瘤的发生发展中可能有着较为密切的联系。
Objective:
To explore the role and clinical significance of vascular endothelial growth factor(VEGF)) and lmainin recepetor (LN-R) in ovarian cancer.
Methods:
Using method of Immunohistochemical SP, the expression of VEGF and LN-R in 19 cases of normal ovarian tissues,23 cases of benign ovarian tumors and 42 cases of ovarian cancer were detected. Statistical analysis was performed with chi-square test and Sperman correlation.The relationship of their expression and pathological type, histological grade, FIGO stage, whether having metastasis were analysised.
Results:
1. The positive expression of VEGF in normal ovarian tissues and benign ovarian tumors and ovarian cance were 10.5%,43.4% and 73.8%,respectively.The positive expression rate of VEGF was significantly different in normal ovarian tissue and benign ovarian tumor tissue (P<0.05) and also was significantly different in benign ovarian tumor and ovarian cancer.(P<0.05)
2. The positive expression rate of VEGF in ovarian serous adenocarcinoma was 76%,that in other ovarian cancers was 70.6%. The difference of VEGF positive expression rate of the two groups was unsignificant (χ2=0.153, P>0.05); The positive expression rate of VEGF in the poorly differentiated group (90.9%) was significantly higher than that in the high differentiated group (55%) (χ2=6.98, P<0.05);The rate of positive expression of VEGF in StageⅢ-Ⅳ(86.9%) was significantly higher than that in the stageⅠ-Ⅱ(57.8%) (χ2=4.54, P<0.05); In the ovarian cancer tissues with lymph nodes or omentum metastasis,the VEGF positive expression rate was 86.4%, significantly higher than that without metastasis (55%)(χ=5.05, P<0.05)
3. LN-R did not express in normal ovarian tissue,LN-R expressed in benign ovarian tumors with low level (4.3%),with high levels of expression in ovarian cancer (76.2%). The positive expression rate of LN-R was significantly different between benign ovarian tumor and ovarian cancer.(P<0.05)
4. The positive expression rate of LN-R in ovarian serous adenocarcinoma was 76%, that in other ovarican cancer was 76.5%. LN-R positive expression rate of the two groups had no significant difference (χ2=0.001, P>0.05); The positive expression rate of LN-R in the poorly differentiated group (90.9%)was significantly higher than that in the high differentiated group(60%) (χ2=5.51, P<0.05); The positive expression of LN-R in stageⅢ-Ⅳ(91.3%) was significantly higher than that in the stageⅠ-Ⅱ(57.8%) (χ2 =6.40, P<0.05); The positive expression rate of LN-R in ovarian cancer with lymph nodes or omentum metastasis(81.8%) was significantly higher than that without lymph nodes or omentum metastasis (50%)(χ2=4.77, P<0.05)
5.VEGF and LN-R show some positive correlation in the occurrence and development of ovarian cancer. (P<0.05)
Conclusions:
1. VEGF and LN-R play a role in the occurrence and development of ovanan cancer.
2. The positive expression of VEGF and LN-R has relationship with clinical stage and histological grading, lymph nodes or omentum metastasis, and has no relationship with pathological type; which indicated that VEGF and LN-R could predict prognostics of ovarian cancer.
3. VEGF and LN-R show some correlation in the occurrence and development of ovarian cancer, which indicated that they cooperated in the occurrence and development of ovarian cancer.
引文
[1]Davidson B, Risberg B, Bemer A, et al. The biological differences between ovarian serous cinoma and diffuse peritoneal malignan mesothelioma[J]. Semin Diagn Pathol,2006,23(1):35-43.
[2]Lee J K, Hong Y J, HanCJ, et al. Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients:Which is the optimal specimen[J] int J Oncol,2000,17(1):149.
[3]李恩孝,吴胤瑛,施播.靶向VEGF治疗恶性肿瘤的研究进展[J].现代肿瘤医学,2006,(03)：120-122.
[4]李丽珍,闰树听.检测卵巢瘤病人血清中血管内皮生长因子浓度的临床意义[J].齐鲁医学检验,2004,3：8-9.
[5]邢爽,刘耀文,罗庆良.血管内皮生长因子靶向治疗抗肿瘤作用机制[J].国际药学研究杂志,2008,35(6)：454-457.
[6]Chan JK, CheungMK, HusainA, TengNN, WestD, WhittemoreAS, BerekJS, Osann K:Patterns and Progress in ovarian cancer over 14 years. Obstetrics & Gynecology 2006,108:521-528.
[7]钟世顺,张振书,李淑梅等.大肠癌血管内皮生长因子的表达及其意义.中华内科杂志,2001,40(8)：514-516.
[8]D Park KH, Choi SE, Eom M, et al.Downregulation of the anaphasepromoting complex (APC)7 in invasive ductal carcinomas of the breast and its clinic opathologic relationships [J].Breast Cancer Res,2005,7(2):238-247.
[9]Elson DA,Thurston G,Huang LE,et al.Induction of hypervascularity without or inflammation in transgenic mice overexpressing hypoxiainducible factor-1 [J].genes Dev,2001,15(19):2520-2532.
[10]Colognato H, Yureheneo PD Form and function:the laminina fmily of heterotrimers[J]. Dev Dyn,2000,Jun,218(2):213-234.
[11]Tanaka M,Narumi K,Isemura M,et al.Expression of the 37 KD laminin binding protein in murine lung tumor cell correlates with tumor angiogenesis[J].Cancer Lett,2000,153(1):161-168.
[12]Givant-Horwitz V,Davidson B,Vande Putte G,et al.Expression of the 67 KD laminin receptor and the alpha intergrin subunit inserous ovarian carcinoma [J]. Clin Exp Metastasis,2003,20(7):599-609.
[13]Gao L,Ding H,Chen L.The relationship between laminin and laminin receptor expression to metastasis and Survival of breast carcinomas [J].Chinese Journal Pathol,1998,27(1):31-34.
[14]龙娟等.层粘连蛋白及其受体在卵巢癌组织中的表达及其临床意义.中华妇产科杂志,2003,38(12)：763-764.
[15]Brekken RA,Thorpe PE.Vascular endothelial growth factor an Vascular targeting of solidtumors.Anticancer Res,2001,2(6B):4221-4229.
[16]Oku T,Tjuvajev JG,Miyagawa T,etal.Tumor growth modulation by sense and antisense vascular endothelial growth factorgene expression: effects on angiogenesis, vascular permeability,Blood volume,blood flow,fluorodeoxyglucose uptake and Proliferation Of human melanoma intracerebral xenografts.Cancer Res,1998,5(18):4185-4192.
[17]陈冰亚,叶大风,谢幸等.卵巢上皮癌细胞中VEGF和VEGFRs的表达与STATs的活化.中华肿瘤杂志,2005,1,27(1)：33-37.
[18]Fodiil Bourahla I,Drubaix I, Robert L, et al. Effect of in ivtro aging on the biosynthesis of glycosam inoglycans by human skinFibro-blasts. Modulation by the lastin laminin receptor[J]. Mech Ageing Dev,1999,106(3):214-60.
[19]汪丛敏,李力,李英惠等,VEGF, VEGFR在卵巢癌中的表达及其临床意义.肿瘤.2006,26(2)：196-198.
[20]Givant-Horwitz V,Davidson B,Van de Putte G,et al.Expression of the 67 kDa laminin receptor and the alpha6 intergrinsuhunit in serous ovarian carcinoma[J].C1 in Exp Metastasis,2003,20(7):599-609.
[21]Sanjuan X, Fernandez PL, Miquel R, et al.overexpression of the 67kD laminin receptor correlates with tumor progression in human colorectal carcinomalJ Pathol,1996,179:376-380.
[22]Castronovo V,Venden BFA, Tackers P, et al. Decreased exp ression of galectin-3 is associated with p rogression of human breast cancer [J].J Pathol,1996,179:43.
[23]Huang SH, Jong A. Evolving role of laminin receptors in microbial pathogenesis and therapeutics of CNS infection. Future Microbiol.2009 Oct;4:959-962.
[24]Sinha R, Unni E, Gauther HE, et al. Methylseleninic acid, apotent growth inhibitor of synchronized mouse mamaryep:tumor cells in vitro[J]. Biochemicology,2001,61(3):311-337.
[25]Sanjuan X, Fernandez PL,Miquel R, et al. Over exp ression of the 67KD Laminin Recep tor correlateswith tumour progression in human colorectal carcinoma[J]. J Pathol,1996,179:376-380.
[26]Vanden BFA, Castronovo V,Menard S, et al. Exp ression of the 67KD Laminin Recep tor in human ovarian cancinomas as defined by amonoclonal antibobyMluC5 [J]. Eur J Cancer,1996,32A:1598-1602.
[27]Givant-Horwitz V,Davidson B, etal.ExPerssion of the 67kDa Laminin receptor and the alpha integrin subunit in serous ovarian carcrinoma. Clin ExP Metastasis.2003;20(7):599-560.
[28]Viacava P,Naccarato AG, Collecchip, et al. The spectrum of 67-KD Laminin recep tor exp ression in breast carcinoma p rogression [J].J Pathol,1997,182:36-44.
[29]Fatehullah A, Doherty C Pivato G, Allen G, Devine L, Nelson J, Timson DJ.Interactions of the 67 kDa laminin receptor and its precursor with laminin.Biosci Rep.2009 Nov 10;30(2):73-79.
[1]Davidson B, Risberg B, Bemer A, et al. The biological differences between ovarian serous c-cinoma and diffuse peritoneal malignan mesothelioma[J]. Semin Diagn Pathol,2006,23(1):35-43.
[2]李恩孝,吴胤瑛,施播.靶向VEGF治疗恶性肿瘤的研究进展[J].现代肿瘤医学,2006,(03)：120-122.
[3]武瑞琴,朱旭东,黄培堂.层粘连蛋白受体研究进展[J].军事医学科学院院刊,2006,30(4)：397-400.
[4]陈冰亚,叶大风,谢幸等.卵巢上皮癌细胞中VEGF和VEGFRs的表达与STATs的活化.中华肿瘤杂志,2005 1,27(1)：33-37.
[5]汪丛敏,李力,李英惠等,VEGF, VEGFR在卵巢癌中的表达及其临床意义肿瘤.2006,26(2)：196-198.
[6]Brekken RA,Thorpe PE.Vascular endothelial growth factor an Vascular targeting of solidtumors.Anticancer Res,2001,2(6B):4221-4229.
[7]Oku T, T juvajev JG, Miyagawa T,etal.Tumor growth modulation by sense and antisense vascular endothelial growth factorgene expression: effects on angiogenesis,vascular permeability,Blood volume,blood flow,fluorodeoxyglucose uptake and Proliferation Of human melanoma intracerebral xenografts.Cancer Res,1998,5(18):4185-4192.
[8]Yabushita H,Shimazu M,Noguchi M,et al.Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peri-toneal dissemination of ovarian carcinoma[J].Oncol Rep,2003,10:89-95.
[9]宋涛,张荣玲,周兰英.血管内皮生长因子在妇科肿瘤中的研究进展[J].当代医学,2008,11：25.
[10]邢爽,刘耀文,罗庆良.血管内皮生长因子靶向治疗抗肿瘤作用机制[J].国际药学研究杂志,2008,35(6)：454-457.
[11]Fulop T, Larbi A.Putative role of 67 kDa elastin-laminin receptor in tumor invasion [J].Semin Cancer Biol,2002,12:219-229.
[12]Fatehullah A, Doherty C Pivato G, Allen G, Devine L, Nelson J, Timson DJ.Interactions of the 67 kDa laminin receptor and its precursor with laminin.Biosci Rep.2009 Nov 10;30(2):73-79
[13]Sanjuan X, Fernandez PL, Miquel R, et al.overexpression of the 672kD laminin receptor correlates with tumor progression in human colorectal carcinomalJ Pathol,1996,179:376-380.
[14]龙娟,陈刚,吴明富.层粘连蛋白及其受体在卵巢癌组织中的表达及其临床意义[J].中华妇产科杂志,2003,38(12)：763-764.
[15]Skiba E,Lebensztejn DM,Werpachowska I,et al.The evaluationc of hyaluronic acid arid laninin concentration in serum in children with chronic hepatitis B treated with lamivudine,unresponsive to previous interferon-alpha therapy[J].PolMerkuriusz Lek,2005;18(105):268-270.
[16]李晓翠,傅艺冰,王斌等.67KDALN-R反义寡甘酸对卵巢癌细胞生物学行为的影响[J].山东大学学报(医学报),2006；44(1)：45-48.
[17]Givant-Horwitz V,Davidson B,Van de Putte G,et al.Expression of the 67 kDa laminin receptor and the alpha6 intergrinsuhunit in serous ovari-an carcinoma[J].Clin Exp Metastasis,2003,20(7):599-609
[18]Givant-Horwitz V,Davidson B,Rcich R.Laninin-induced signaling in tuamr cells:the role of the M (r) 67,000laminini receptor [J]. Cancer Res,2004;64(10):3572-3579.
[19]卢运萍,张阿丽,王世宣,等,卵巢癌VEGF的过度表达及肿瘤浸润转移机制的探讨,中华妇产科杂志,2002；37(5)：294-295.
[20]Ardini E,Sporchia B,Pollegioni L,et al.Identification of a novel function for 67kDa lamlnin receptor:increase inlaninin degradation rate and release of motility fragments [J].Cancer Res,2002;62(5):1321-132
[2]Lee J K, Hong Y J, HanCJ, et al. Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients:Which is the optimal specimen[J] int J Oncol,2000,17(1):149.
[3]李恩孝,吴胤瑛,施播.靶向VEGF治疗恶性肿瘤的研究进展[J].现代肿瘤医学,2006,(03)：120-122.
[4]李丽珍,闰树听.检测卵巢瘤病人血清中血管内皮生长因子浓度的临床意义[J].齐鲁医学检验,2004,3：8-9.
[5]邢爽,刘耀文,罗庆良.血管内皮生长因子靶向治疗抗肿瘤作用机制[J].国际药学研究杂志,2008,35(6)：454-457.
[6]Chan JK, CheungMK, HusainA, TengNN, WestD, WhittemoreAS, BerekJS, Osann K:Patterns and Progress in ovarian cancer over 14 years. Obstetrics & Gynecology 2006,108:521-528.
[7]钟世顺,张振书,李淑梅等.大肠癌血管内皮生长因子的表达及其意义.中华内科杂志,2001,40(8)：514-516.
[8]D Park KH, Choi SE, Eom M, et al.Downregulation of the anaphasepromoting complex (APC)7 in invasive ductal carcinomas of the breast and its clinic opathologic relationships [J].Breast Cancer Res,2005,7(2):238-247.
[9]Elson DA,Thurston G,Huang LE,et al.Induction of hypervascularity without or inflammation in transgenic mice overexpressing hypoxiainducible factor-1 [J].genes Dev,2001,15(19):2520-2532.
[10]Colognato H, Yureheneo PD Form and function:the laminina fmily of heterotrimers[J]. Dev Dyn,2000,Jun,218(2):213-234.
[11]Tanaka M,Narumi K,Isemura M,et al.Expression of the 37 KD laminin binding protein in murine lung tumor cell correlates with tumor angiogenesis[J].Cancer Lett,2000,153(1):161-168.
[12]Givant-Horwitz V,Davidson B,Vande Putte G,et al.Expression of the 67 KD laminin receptor and the alpha intergrin subunit inserous ovarian carcinoma [J]. Clin Exp Metastasis,2003,20(7):599-609.
[13]Gao L,Ding H,Chen L.The relationship between laminin and laminin receptor expression to metastasis and Survival of breast carcinomas [J].Chinese Journal Pathol,1998,27(1):31-34.
[14]龙娟等.层粘连蛋白及其受体在卵巢癌组织中的表达及其临床意义.中华妇产科杂志,2003,38(12)：763-764.
[15]Brekken RA,Thorpe PE.Vascular endothelial growth factor an Vascular targeting of solidtumors.Anticancer Res,2001,2(6B):4221-4229.
[16]Oku T,Tjuvajev JG,Miyagawa T,etal.Tumor growth modulation by sense and antisense vascular endothelial growth factorgene expression: effects on angiogenesis, vascular permeability,Blood volume,blood flow,fluorodeoxyglucose uptake and Proliferation Of human melanoma intracerebral xenografts.Cancer Res,1998,5(18):4185-4192.
[17]陈冰亚,叶大风,谢幸等.卵巢上皮癌细胞中VEGF和VEGFRs的表达与STATs的活化.中华肿瘤杂志,2005,1,27(1)：33-37.
[18]Fodiil Bourahla I,Drubaix I, Robert L, et al. Effect of in ivtro aging on the biosynthesis of glycosam inoglycans by human skinFibro-blasts. Modulation by the lastin laminin receptor[J]. Mech Ageing Dev,1999,106(3):214-60.
[19]汪丛敏,李力,李英惠等,VEGF, VEGFR在卵巢癌中的表达及其临床意义.肿瘤.2006,26(2)：196-198.
[20]Givant-Horwitz V,Davidson B,Van de Putte G,et al.Expression of the 67 kDa laminin receptor and the alpha6 intergrinsuhunit in serous ovarian carcinoma[J].C1 in Exp Metastasis,2003,20(7):599-609.
[21]Sanjuan X, Fernandez PL, Miquel R, et al.overexpression of the 67kD laminin receptor correlates with tumor progression in human colorectal carcinomalJ Pathol,1996,179:376-380.
[22]Castronovo V,Venden BFA, Tackers P, et al. Decreased exp ression of galectin-3 is associated with p rogression of human breast cancer [J].J Pathol,1996,179:43.
[23]Huang SH, Jong A. Evolving role of laminin receptors in microbial pathogenesis and therapeutics of CNS infection. Future Microbiol.2009 Oct;4:959-962.
[24]Sinha R, Unni E, Gauther HE, et al. Methylseleninic acid, apotent growth inhibitor of synchronized mouse mamaryep:tumor cells in vitro[J]. Biochemicology,2001,61(3):311-337.
[25]Sanjuan X, Fernandez PL,Miquel R, et al. Over exp ression of the 67KD Laminin Recep tor correlateswith tumour progression in human colorectal carcinoma[J]. J Pathol,1996,179:376-380.
[26]Vanden BFA, Castronovo V,Menard S, et al. Exp ression of the 67KD Laminin Recep tor in human ovarian cancinomas as defined by amonoclonal antibobyMluC5 [J]. Eur J Cancer,1996,32A:1598-1602.
[27]Givant-Horwitz V,Davidson B, etal.ExPerssion of the 67kDa Laminin receptor and the alpha integrin subunit in serous ovarian carcrinoma. Clin ExP Metastasis.2003;20(7):599-560.
[28]Viacava P,Naccarato AG, Collecchip, et al. The spectrum of 67-KD Laminin recep tor exp ression in breast carcinoma p rogression [J].J Pathol,1997,182:36-44.
[29]Fatehullah A, Doherty C Pivato G, Allen G, Devine L, Nelson J, Timson DJ.Interactions of the 67 kDa laminin receptor and its precursor with laminin.Biosci Rep.2009 Nov 10;30(2):73-79.
[1]Davidson B, Risberg B, Bemer A, et al. The biological differences between ovarian serous c-cinoma and diffuse peritoneal malignan mesothelioma[J]. Semin Diagn Pathol,2006,23(1):35-43.
[2]李恩孝,吴胤瑛,施播.靶向VEGF治疗恶性肿瘤的研究进展[J].现代肿瘤医学,2006,(03)：120-122.
[3]武瑞琴,朱旭东,黄培堂.层粘连蛋白受体研究进展[J].军事医学科学院院刊,2006,30(4)：397-400.
[4]陈冰亚,叶大风,谢幸等.卵巢上皮癌细胞中VEGF和VEGFRs的表达与STATs的活化.中华肿瘤杂志,2005 1,27(1)：33-37.
[5]汪丛敏,李力,李英惠等,VEGF, VEGFR在卵巢癌中的表达及其临床意义肿瘤.2006,26(2)：196-198.
[6]Brekken RA,Thorpe PE.Vascular endothelial growth factor an Vascular targeting of solidtumors.Anticancer Res,2001,2(6B):4221-4229.
[7]Oku T, T juvajev JG, Miyagawa T,etal.Tumor growth modulation by sense and antisense vascular endothelial growth factorgene expression: effects on angiogenesis,vascular permeability,Blood volume,blood flow,fluorodeoxyglucose uptake and Proliferation Of human melanoma intracerebral xenografts.Cancer Res,1998,5(18):4185-4192.
[8]Yabushita H,Shimazu M,Noguchi M,et al.Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peri-toneal dissemination of ovarian carcinoma[J].Oncol Rep,2003,10:89-95.
[9]宋涛,张荣玲,周兰英.血管内皮生长因子在妇科肿瘤中的研究进展[J].当代医学,2008,11：25.
[10]邢爽,刘耀文,罗庆良.血管内皮生长因子靶向治疗抗肿瘤作用机制[J].国际药学研究杂志,2008,35(6)：454-457.
[11]Fulop T, Larbi A.Putative role of 67 kDa elastin-laminin receptor in tumor invasion [J].Semin Cancer Biol,2002,12:219-229.
[12]Fatehullah A, Doherty C Pivato G, Allen G, Devine L, Nelson J, Timson DJ.Interactions of the 67 kDa laminin receptor and its precursor with laminin.Biosci Rep.2009 Nov 10;30(2):73-79
[13]Sanjuan X, Fernandez PL, Miquel R, et al.overexpression of the 672kD laminin receptor correlates with tumor progression in human colorectal carcinomalJ Pathol,1996,179:376-380.
[14]龙娟,陈刚,吴明富.层粘连蛋白及其受体在卵巢癌组织中的表达及其临床意义[J].中华妇产科杂志,2003,38(12)：763-764.
[15]Skiba E,Lebensztejn DM,Werpachowska I,et al.The evaluationc of hyaluronic acid arid laninin concentration in serum in children with chronic hepatitis B treated with lamivudine,unresponsive to previous interferon-alpha therapy[J].PolMerkuriusz Lek,2005;18(105):268-270.
[16]李晓翠,傅艺冰,王斌等.67KDALN-R反义寡甘酸对卵巢癌细胞生物学行为的影响[J].山东大学学报(医学报),2006；44(1)：45-48.
[17]Givant-Horwitz V,Davidson B,Van de Putte G,et al.Expression of the 67 kDa laminin receptor and the alpha6 intergrinsuhunit in serous ovari-an carcinoma[J].Clin Exp Metastasis,2003,20(7):599-609
[18]Givant-Horwitz V,Davidson B,Rcich R.Laninin-induced signaling in tuamr cells:the role of the M (r) 67,000laminini receptor [J]. Cancer Res,2004;64(10):3572-3579.
[19]卢运萍,张阿丽,王世宣,等,卵巢癌VEGF的过度表达及肿瘤浸润转移机制的探讨,中华妇产科杂志,2002；37(5)：294-295.
[20]Ardini E,Sporchia B,Pollegioni L,et al.Identification of a novel function for 67kDa lamlnin receptor:increase inlaninin degradation rate and release of motility fragments [J].Cancer Res,2002;62(5):1321-132